<table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="FONT-FAMILY: times; TEXT-ALIGN: justify"><font size="2"><b>Note&nbsp;12 &#151; Goodwill and Intangible Assets </b></font></p>
<p style="FONT-FAMILY: times; TEXT-ALIGN: justify"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abbott recorded goodwill of approximately $3.4&nbsp;billion in 2010 related to the acquisitions of Solvay's pharmaceuticals business, Piramal Healthcare Limited's Healthcare Solutions business, Facet Biotech and STARLIMS Technologies. Goodwill related to the Solvay, Piramal and Facet acquisitions was allocated to the Pharmaceutical Products segment. In addition, in 2010, Abbott paid $250&nbsp;million to Boston Scientific as a result of the approval to market the </font><font size="2"><i>Xience V</i></font><font size="2"> drug-eluting stent in Japan, resulting in an increase in goodwill in the Vascular Products segment. Abbott recorded goodwill of approximately $2.2&nbsp;billion in 2009 related to the acquisitions of Advanced Medical Optics,&nbsp;Inc., Ibis Biosciences,&nbsp;Inc., Visiogen,&nbsp;Inc. and Evalve,&nbsp;Inc. Goodwill of approximately $120&nbsp;million related to the Ibis acquisition was allocated to the Diagnostic Products segment and goodwill of approximately $160&nbsp;million related to the Evalve acquisition was allocated to the Vascular Products segment. In connection with the dissolution of the TAP Pharmaceutical Products&nbsp;Inc. (TAP) joint venture in 2008, Abbott recorded approximately $350&nbsp;million of goodwill related to the Pharmaceutical Products segment. In 2008, Abbott paid $250&nbsp;million to Boston Scientific as a result of the FDA's approval to market the </font><font size="2"><i>Xience V</i></font><font size="2"> drug-eluting stent in the U.S., resulting in an increase in goodwill in the Vascular Products segment. Foreign currency translation and other adjustments (decreased) increased goodwill in 2010, 2009 and 2008 by $(879)&nbsp;million, $997&nbsp;million and $(677)&nbsp;million, respectively. The amount of goodwill related to reportable segments at December&nbsp;31, 2010 was $9.4&nbsp;billion for the Pharmaceutical Products segment, $208&nbsp;million for the Nutritional Products segment, $383&nbsp;million for the Diagnostic Products segment, and $2.6&nbsp;billion for the Vascular Products segment. Goodwill was reduced by approximately $64&nbsp;million in connection with the sale of Abbott's spine business in 2008. There were no other significant reductions of goodwill relating to impairments or disposal of all or a portion of a business. </font></p>
<p style="FONT-FAMILY: times; TEXT-ALIGN: justify"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The gross amount of amortizable intangible assets, primarily product rights and technology was $17.3&nbsp;billion, $10.8&nbsp;billion and $9.4&nbsp;billion as of December&nbsp;31, 2010, 2009 and 2008, respectively, and accumulated amortization was $6.5&nbsp;billion, $5.1&nbsp;billion and $4.2&nbsp;billion as of December&nbsp;31, 2010, 2009 and 2008, respectively. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $1.4&nbsp;billion and $610&nbsp;million at December&nbsp;31, 2010 and 2009, respectively. The estimated annual amortization expense for intangible assets recorded at December&nbsp;31, 2010 is approximately $1.6&nbsp;billion in 2011, $1.3&nbsp;billion in 2012, $1.1&nbsp;billion in 2013, $895&nbsp;million in 2014 and $790&nbsp;million in 2015. Amortizable intangible assets are amortized over 2 to 30&nbsp;years (average 12&nbsp;years). </font></p></td></tr></table>
